Paola Zanovello

Istituto Oncologico Veneto — Italy

Immunology and Microbiology · Life Sciences

50h-index13.7kcitations236works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(81), CAR-T cell therapy research(51), Immune Cell Function and Interaction(46), Virus-based gene therapy research(33), Cancer Immunotherapy and Biomarkers(30)

Publications236 total

Supplementary Figure 2 from <i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer
2023Open Access
Supplementary Figure 1 from <i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer
2023Open Access
Supplementary Figure 4 from <i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer
2023Open Access
Supplementary Figure Legends 1-9 from Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
2023Open Access
Data from <i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer
2023Open Access
Data from <i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer
2023Open Access
Supplementary Figure 6 from Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor α Usage by Melanoma-specific CD8<sup>+</sup> T Lymphocytes
2023Open Access
Supplementary Methods, Figures 1-3 from Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors
2023Open Access
Supplementary Figures 1-9 from Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
2023Open Access
Supplementary Figure 3 from Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor α Usage by Melanoma-specific CD8<sup>+</sup> T Lymphocytes
2023Open Access
Supplementary Figure 3 from <i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer
2023Open Access
Supplementary Figures 1-4 from <i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer
2023Open Access
Data from Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors
2023Open Access
Supplementary Methods from Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
2023Open Access
Data from Common Cancer Biomarkers
2023Open Access
Supplementary Figure 4 from Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor α Usage by Melanoma-specific CD8<sup>+</sup> T Lymphocytes
2023Open Access
Data from Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
2023Open Access
Supplementary Figure 4 from <i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer
2023Open Access
Supplementary Figure 2 from <i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer
2023Open Access
Supplementary Table from Common Cancer Biomarkers
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Vincenzo Bronte(31), Susanna Mandruzzato(13), Ilaria Marigo(12), Paolo Serafini(11), Antonio Rosato(9), Luigi Dolcetti(8), Francesco Di Virgilio(7), Stefano Ugel(6), Elisa Apolloni(6), Silvio Bicciato(5), Carmela De Santo(5), Giovanni Esposito(5), Stefania Bortoluzzi(5), Paola Pizzo(5), Giuseppe Basso(4), Alessandra Mazzoni(4), David M. Segal(4), Elisa Peranzoni(4), Simone Mocellin(4), Donato Nitti(4)